Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TenoMiR in lateral epicondylitis
NCT06192927Phase 2Completed
- Sponsor
- Causeway Therapeutics
- Start
- Apr 2024
- Primary completion
- Mar 2025
- Modality
- Antisense DNA, miRNA Mimics, Small Interfering RNA (siRNA)
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of TenoMiR in Lateral Epicondylitis (LET) (3 arms), sponsored by Causeway Therapeutics. Primary endpoint: Numeric Rating Scale pain score at 90 days. Started Apr 2024; status: completed.
02
Drugs
TenoMiR
03
Conditions
Lateral Epicondylitis (LET)
Beyond the preview
Go deeper on NCT06192927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06192927.